

# In Vivo Assessment of Drug Efficacy against Mycobacterium abscessus Using the Embryonic Zebrafish Test System

Audrey Bernut, Vincent Le Moigne, Tiffany Lesne, Georges Lutfalla, Jean-Louis Herrmann, Laurent Kremer

## ▶ To cite this version:

Audrey Bernut, Vincent Le Moigne, Tiffany Lesne, Georges Lutfalla, Jean-Louis Herrmann, et al.. In Vivo Assessment of Drug Efficacy against Mycobacterium abscessus Using the Embry-onic Zebrafish Test System. Antimicrobial Agents and Chemotherapy, 2014, 58 (7), pp.4054-4063. 10.1128/AAC.00142-14. hal-02088311

# HAL Id: hal-02088311 https://hal.umontpellier.fr/hal-02088311

Submitted on 11 Apr 2019  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	In vivo assessment of drug efficacy against Mycobacterium
2	abscessus using the embryonic zebrafish test system
3	
4	Audrey Bernut <sup>1</sup> , Vincent Le Moigne <sup>3</sup> , Tiffany Lesne <sup>1</sup> , Georges Lutfalla <sup>1</sup> ,
5	Jean-Louis Herrmann <sup>3</sup> and Laurent Kremer <sup>1,2,#</sup>
6	
7	
8	<sup>1</sup> Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, CNRS
9	UMR5235, Université Montpellier 2, Montpellier, France ;
10	<sup>2</sup> Inserm, DIMNP, Place Eugène Bataillon, 34095 Montpellier Cedex 05, France.
11	<sup>3</sup> EA3647-EPIM, UFR des Sciences de La Santé; Université de Versailles St Quentin, 2 avenue de
12	la Source de la Bièvre, 78180 Montigny le Bretonneux, France.
13	
14	
15	<sup>#</sup> To whom correspondence should be addressed:
16	Tel: (+33) 4 67 14 33 81, Fax: (+33) 4 67 14 42 86, E-mail: <u>laurent.kremer@univ-montp2.fr</u>
17	
18	Keywords: M. abscessus, zebrafish, drug testing, optical imaging, infection
19	
20	Running title: In vivo imaging for anti-M. abscessus drug testing
21	
22	

23 ABSTRACT

24

Mycobacterium abscessus is responsible of a wide spectrum of clinical syndromes and is one of 25 the most intrinsically drug-resistant mycobacterial species. Recent evaluation of the in vivo 26 therapeutic efficacy of the few potentially active antibiotics against *M. abscessus* was 27 essentially performed using immune-compromised mice. Herein, we assessed the feasibility 28 29 and sensitivity of fluorescence imaging for monitoring the *in vivo* activity of drugs against acute M. abscessus infection using zebrafish embryos. A protocol was developed where 30 clarithromycin and imipenem were directly added to water containing fluorescent M. 31 abscessus-infected embryos in a 96-well plate format. The status of the infection with 32 increasing drug concentrations was visualized on a spatiotemporal level. Drug efficacy was 33 34 assessed quantitatively by determining the index of protection, the bacterial burden by CFU 35 plating and by monitoring the number of abscesses through fluorescence measurements. Both drugs were active in infected embryos and were capable of significantly increasing embryo 36 survival in a dose-dependent manner. Protection from bacterial killing correlated with 37 38 restricted mycobacterial growth in the drug-treated larvae and with reduced pathophysiological symptoms, such as the number of abscesses within the brain. In conclusion, we present here a 39 40 new and efficient method for testing and compare the *in vivo* activity of two clinically-relevant drugs based on a fluorescent reporter strain in zebrafish embryos. This approach could be 41 applied to a rapid determination of *in vivo* drug susceptibility profile of clinical isolates and to 42 43 assess the preclinical efficacy of new compounds against *M. abscessus*.

45 **INTRODUCTION** 

46

*M. abscessus* (*Mabs*) is an emerging pathogen and the etiological agent of a wide spectrum 47 of infections in humans. It is responsible for severe chronic pulmonary and disseminated 48 infections, mostly in immunosuppressed and in cystic fibrosis (CF) patients (1), and cutaneous 49 diseases, often post-traumatic and post-surgical. This neglected pathogen causes a higher 50 fatality rate compared to other RGMs and the infection of CF patients is becoming a major 51 health-related issue in most CF centers worldwide (2). Mabs infections occur in early childhood 52 (3), are severe and sometimes fatal, especially following transplantation (4-6), and have the 53 54 potential to cause outbreaks of infection (6). Mabs is also the main RGM responsible for nosocomial and iatrogenic infections in humans (post-injection abscesses, cardiac surgery, and 55 56 plastic surgery) (7-9). It has also been reported to cross the blood-brain barrier and to cause 57 important central nervous system (CNS) lesions. Although a rapid grower, Mabs possesses several important pathogenic traits such as the ability to i) persist silently for years and even 58 decades (10) in the human host, and to ii) induce lung disease associated with caseous lesions 59 60 and granuloma formation in lung parenchyma (11, 12).

The major issue with Mabs relies on its intrinsic resistance to the majority of available 61 62 antibiotics. The American Thoracic Society has recommended different groups of agents, namely macrolides (clarithromycin), aminoglycosides (amikacin), cephamycins (cefoxitin) and 63 carbapenems (imipenem) for treatment of *Mabs* infections (13). Patients with severe infections 64 65 are generally treated with long courses of combinatorial antibiotic therapy, often accompanied by surgical resection. As antibiotic susceptibility testing is not fully standardized, the clinical 66 response to drugs does not correlate well with *in vitro* susceptibility test results and failure 67 occurs frequently despite administration of two or three antibiotics for several months (14). 68

This further emphasizes the need of suitable animal models (15, 16). In addition, different clinical isolates of this emerging pathogen are not uniformly susceptible to the currently used antibiotics (17). As a consequence, an optimal regimen to cure the *Mabs* infections has not been yet established.

Thanks to the recent availability of efficient genetic tools (18), Mabs has been proposed as 73 an attractive experimental model to study non-tuberculous mycobacteria associated diseases 74 (1). Our poor understanding of the pathogenesis of *Mabs*, essentially hampered by the 75 restricted panel of cellular/animal models available, prompted us to develop the zebrafish 76 model of infection to describe the chronology of *Mabs* infection (19). In particular, the 77 78 Mabs/zebrafish couple already provided important insights regarding the pathogenesis of Mabs such as the unexpected tropism for the CNS, a finding relevant in the light of recent clinical 79 80 studies reporting the presence of *Mabs* in the CNS of infected human patients (20, 21). Since 81 infection foci/abscesses within the CNS, particularly the brain, appear very rapidly and are very easy to detect and visualize, we reasoned that this alternative model could represent a valuable 82 83 and cheap system to evaluate and compare the in vitro and in vivo activity of drugs against Mabs. Such a simple and innovative system would be particularly suited for screening active 84 85 molecules and/or antibacterial activity assessment, representing a critical step in the context of 86 drug discovery, urgent in the case of Mabs.

Here, we report on the development of experimental conditions for *in vivo* imaging of *Mabs* and demonstrate that it is compatible with *in vivo* observations, at a spatiotemporal level, of the effects of drug treatment on the infection process. This represents a unique biological model that allows non-invasive observations to evaluate, in real time, the efficacy of antibiotics in living infected vertebrates, a system that could be applied to high-throughput *in vivo* testing of drug efficacy against the most drug-resistant mycobacterial species.

93

#### 94 MATERIALS AND METHODS

95

## 96

## M. abscessus strains and growth conditions

The rough variant of *M. abscessus sensu stricto* strain CIP104536<sup>T</sup> (ATCC19977T) was grown 97 30°C Middlebrook broth supplemented 98 at in 7H9 with 10% Oleic acid/Albumin/Dextrose/Catalase (OADC) enrichment and 0.05% Tween 80 (7H9<sup>T</sup>) or on 99 Middlebrook 7H10 agar containing 10% OADC. Recombinant Mabs carrying pTEC27 (Addgene, 100 plasmid 30182) that allows to express tdTomato under the control of a strong mycobacterial 101 promoter were grown in the presence of hygromycin 500 mg/L (19). 102

103

## 104 Mice experiments and CFU counting

105 6-8 weeks old BALB/c mice were divided in groups of 5-7 mice and used for either 106 intravenous (*i.v.*) or aerosol challenges. Inocula were prepared from rapidly thawed frozen aliquots, and bacterial clumps were eliminated by iterative passages through a 29.5-gauge 107 insulin needle (Becton Dickinson). Bacterial suspensions were then diluted in phosphate buffer 108 109 saline (PBS). For *i.v.* inoculations, 10<sup>6</sup> CFU (in 200 μl) were injected into the lateral tail/caudal vein, as previously described (22, 23). Pulmonary infections were achieved with aerosolized 110 111 *Mabs* using an aerosol generator, equipped with a Micro Mist<sup>®</sup> small volume nebulizer (Hudson RCI-Teleflex medical) containing 6 ml of bacterial solution at  $4 \times 10^7$  CFU/ml. Pre-sleeping mice 112 (isoflurane<sup>®</sup> Abbott) were anesthetized with 200 μl of Hypnomidate (Etomidate<sup>®</sup>, Janssen-Cilag) 113 and placed into an opened 50 ml syringe fixed on the top of a closed compartment containing 114 115 the nebulizer. In this device, nebulization lasted for 15 min to vaporize the entire bacterial suspension. Lungs, liver and spleen were collected in PBS, crushed and 10-fols serial dilutions 116 were plated on Middlebrook 7H11 plates for CFU counting, as previously described (22, 23). 117

Plates were then incubated at 37°C for up to 7 days. The results were expressed as the mean
Log<sub>10</sub> CFU per organ.

120

#### 121 Minimal inhibitory concentrations

Antibiotics powder tested in drug susceptibility assays were pharmaceutical standards for 122 imipenem/cilastatin (Mylan) or clarithromycin (Sigma-Aldrich). Stock solutions were dissolved 123 in water (imipenem) or in DMSO (clarithromycin). Drug susceptibility testing was also 124 determined using the microdilution method, in cation-adjusted Mueller-Hinton broth, 125 according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (24). In addition, 126 the susceptibility profile was also determined on LB agar supplemented with increasing 127 concentrations of the compounds. Serial 10-fold dilutions of each actively growing culture were 128 129 plated and incubated at 37°C for 3-4 days and the MIC was defined as the minimum concentration required to inhibiting 99% of the growth. 130

131

## 132 Zebrafish care

All zebrafish experiments were done at the University Montpellier 2, according to 133 134 European Union guidelines for handling of laboratory animals (http://ec.europa.eu/environment/chemicals/lab animals/home en.htm) and approved by the 135 Direction Sanitaire et Vétérinaire de l'Hérault and Comité d'Ethique pour l'Expérimentation 136 137 Animale de la région Languedoc Roussillon (CEEA-LR) under the reference CEEA-LR-13007. 138 Experiments were performed using the *golden* ZF mutant (25). Eggs were obtained by natural 139 spawning and incubated at 28.5°C in water with 60 mg/L Ocean salts. Ages of the embryos are expressed as hours post fertilization (hpf). 140

## 142 Microinjection of *M. abscessus* into embryos

Mid-log phase cultures of Mabs expressing tdTomato were centrifuged, washed and 143 resuspended in PBS supplemented with 0.05% Tween-80 (PBS<sup>T</sup>). Bacterial suspensions were 144 then homogenized through a 26-gauge needle and sonicated three times for 10s and the 145 remaining clumps were allowed to settle down to for 5-10 min. Bacteria were concentrated to 146 147 an OD<sub>600</sub> of 1 in PBS<sup>T</sup> and *i.v.* injected (≈2nL containing 300 CFU) into the caudal vein in 30hpf embryos previously dechorionated and anesthetized. To follow infection kinetics and embryo 148 survival, infected larvae were transferred into 96 well plates (2 embryos/plate) and incubated 149 at 28.5°C. The inoculum size was checked by injection of 2nL in sterile PBS<sup>T</sup> and plated on 150 Middlebrook 7H10 agar containing 10% OADC supplemented with hygromycin 500 mg/L. 151

152

153

## Drug efficacy assessment in *Mabs*-infected ZF

154 Clarythromycin and imipenem/cilastatin were added at one day post-infection (dpi), directly into the water containing the embryos. Three doses were tested, corresponding to 155 1.7X, 17X and 170X the MIC of clarithromycin and 0.5X, 5X or 28X the MIC of imipenem, based 156 157 on the values determined using the microdilution method (Table S1). In vivo drug efficacy was determined for each concentration by following i) the bacterial burdens, ii) the kinetic of 158 159 embryo survival, iii) the evolution of the infection foci/abscesses within the CNS and iv) the 160 effect on bacterial cord formation/reduction. Survival curves were determined by recording dead embryos (no heartbeat) every day for up to 13 days. Regarding the kinetic of 161 mycobacterial loads, groups of three infected embryos were collected, lysed individually in 2% 162 Triton X100- PBS<sup>T</sup> with a 26-gauge needle (15 up-and-down sequences) and resuspended in 163 PBS<sup>T</sup>. Several 10-fold dilutions of homogenates were plated on Middlebrook 7H10 agar 164 supplemented with 10% OADC, the appropriate antibiotics and added of mix of "BBL<sup>™</sup> MGIT<sup>™</sup> 165

PANTA<sup>™</sup> (Becton-Dickinson) using as recommended by the supplier. CFU were enumerated
 after 4 days of incubation at 30°C. This procedure was repeated at 0, 3, 5 dpi.

168

## 169 Microscopy

Widefield bright-field and fluorescence live microscopy of infected embryos were 170 performed using an Olympus MVX10 epifluorescent microscope equipped with a X-Cite<sup>®</sup>120Q 171 (Lumen Dynamics) 120W mercury light source. Images are acquired with a digital color camera 172 (Olympus XC50) and processed using CellSens software (Olympus). Fluorescence filter cube 173 TRITC-MVX10 is used for detection of red light. For live imaging, anesthetized infected embryos 174 were positioned in dishes and immobilized with 1% low-melting point agarose solution covering 175 the entire larvae then immobilized embryos are immersed with fish water containing tricaine 176 177 for direct visualization.

178

## 179 Image Processing and Analysis

Final images analysis and visualization are performed using GIMP 2.6 freeware to merge fluorescent and DIC images and to adjust levels and brightness and to remove out-of-focus background fluorescence.

183

## 184 Statistical Analyses

Statistical analyses of comparisons between Kaplan-Meier survival curves were performed using the log rank test with Prism 4.0 (Graphpad, Inc). CFU counts and quantifications experiments were analyzed using one-way ANOVA and Fisher's exact test, respectively. Statistical significance was assumed at p values <0.05.

#### 190 **RESULTS**

191

## M. abscessus fails to establish a persistent infection in BALB/c mice

Experiments were first aimed to determine the colonization rate of Mabs in a murine 192 pulmonary infection model (Figure 1A). Aerosol infections of BALB/c mice was characterized by 193 an initial and rapid increase of the bacterial burden from 1-3 days post-infection (dpi) in the 194 lungs, followed by a phase of infection control that leads to a reduction (starting after 3dpi) and 195 almost complete clearance of the bacilli at 27dpi. Very few bacteria were detected within the 196 spleen or the liver of infected mice. The colonization profile after an *i.v.* challenge showed that 197 bacilli were primarily found in the liver at 1dpi and to a lesser extent in the spleen and the lungs 198 (Figure 1B). All heavily infected organs rapidly underwent a progressive reduction in the CFU 199 levels with a 3-Log<sub>10</sub> CFU decrease in the liver and the lungs at 30dpi, highlighting a transient 200 201 colonization process. These results indicate that the course of infection in immune-competent 202 mice consists mostly as a progressive eradication of the pathogen. This model would, therefore, require to testing a very large number of animals to insure that the observed CFU decrease 203 204 results to the antibiotic regimen rather than to the natural course of infection. Consequently, 205 wild-type BALB/c mice are not well adapted to investigate the in vivo efficacy of therapeutic treatments. Therefore, the use of alternative animal models susceptible to Mabs infection, 206 207 permissive to bacterial replication and leading to the development of infection foci/abscesses 208 and death would be particularly advantageous. We hypothesized that ZF larvae may represent a valuable system for *in vivo* assessments of drugs against *Mabs*. 209

210

## 211 Zebrafish larvae for *in vivo* assessment of drug activity in *M. abscessus*

To assess *in vivo* antimycobacterial drug activity against *Mabs* in ZF larvae, an experimental protocol has been established (Figure 2). tdTomato-expressing *Mabs*, exhibiting red 214 fluorescence, were *i.v.* injected in the caudal vein of embryos at 30 hours post-fertilization (hpf) and transferred into 96-well plates. Antibiotic were then directly added at 1dpi to the water 215 216 containing the infected embryos and the drug-supplemented water was then changed on a daily basis for 5 days. Daily monitoring of mortality as well as determination of the bacterial 217 burden at various time points were used as phenotypic read-outs. Thanks to the optical 218 219 transparency of the embryos, the effect of the antibiotic treatment on evolution of the clinical 220 signs of infection was also recorded by fluorescence microscopy. Since most infected Mabs infected-embryos developed infection abscesses within the CNS, especially the brain (Figure 2), 221 222 the chemotherapeutic activity of the antibiotics was particularly easy to observe, on an 223 individual basis, during the entire period of drug treatment. Drug-mediated toxicity was also investigated by determining the survival curves of non-infected embryos treated with 224 225 increasing drug doses. We have previously shown that the rough Mabs exhibits a marked 226 neurotropism with massive abscesses within the CNS (19), thus prompting us to assess the activity of drugs in *Mabs*-infected embryos with a special emphasis on infection within the CNS. 227

228

## 229 Minimal inhibitory concentrations of antimycobacterial drugs against *M. abscessus*

We first determined the *in vitro* activity of various drugs, including antitubercular agents, 230 231 against *Mabs* using the microdilution in cation-adjusted Mueller-Hinton broth, according to the Clinical and Laboratory Standards Institute guidelines (24). Table S1 shows that the activity 232 varies considerably, in agreement with other studies. The first-line antitubercular drug isoniazid 233 and second-line drug thiacetazone appeared inactive against Mabs. Among the few clinically 234 used drugs for the treatment of Mabs infection, cefoxitin, amikacin, imipenem and 235 236 erythromycin exhibit moderate activity *in vitro* on agar plates with MICs ranging from 60-125  $\mu$ M, whereas clarithromycin demonstrated the highest activity with an MIC value of 4  $\mu$ M. 237

Because clarithromycin and imipenem exhibit different physicochemical properties (high molecular weight and hydrophobicity for clarithromycin versus low molecular weight and hydrophilicity for imipenem), they were further investigated for their *in vivo* therapeutic efficacy in *Mabs*-infected ZF.

242

243

## In vivo susceptibility of M. abscessus to clarithromycin

Due to insufficient information concerning the mechanisms of drug uptake by ZF 244 embryos/larvae, a wide range of concentrations, spanning from 6.6 µM-668 µM of 245 clarithromycin (corresponding to 1.7X to 170X the in vitro MIC value obtained using the 246 microdilution method) was tested. Supplementation of the embryo-containing water with low 247 or intermediate doses (1.7X and 17X the MIC, respectively) displayed no toxicity as measured 248 249 by larval survival, while used at the highest dose tested (170X MIC), a 10% reduction in larval 250 survival was observed at 9dpi, with respect to the control group in which water was supplemented with 1% DMSO (26) (Figure 3A). Embryos that develop in the presence of high 251 doses of clarithromycin had a curved body trunk with uninflated swim bladder as compared to 252 253 the DMSO control embryos (Figure 3A, inset). These phenotypic alterations were hardly observed when exposed to intermediate or low doses of clarithromycin (data not shown). 254

Nevertheless, since these developmental abnormalities essentially occurred at the highest doses, we next assessed the *in vivo* efficacy of clarithromycin in *Mabs*-infected embryos. No significant increased survival was found when infected-embryos were exposed to low and intermediate drug concentrations (Figure 3B). In contrast, high doses extended the life span of infected embryos and fully protected the infected embryos up to 9dpi, when the first embryo started to dye, which coincidently, corresponded to the toxicity-induced-killing effect (Figure 3A). This shows that clarithromycin, using the highest regimen, is efficient in the ZF test system. 262

#### Effects of clarithromycin on ZF survival, bacterial burden and abscesses

Increased survival was associated with lower bacterial burdens after 3dpi in the presence 263 of the highest dose (170X MIC), as determined quantitatively by CFU plating (Figure 3C), 264 whereas treatment with the low or intermediate doses failed to restrict mycobacterial growth. 265 In vivo drug efficacy was next monitored by time-lapse fluorescence microscopy (Figure 3D). 266 Injection of *Mabs* led to the appearance of rapidly growing infection foci and abscesses in the 267 larval brain at 3dpi, as reported previously (19). Imaging the same infected embryos at 3 and 268 5dpi revealed that abscesses within the brain were already reduced at 3dpi when treated with 269 high drug concentrations and this effect in reducing the clinical signs of the infection was even 270 271 more accentuated at 5dpi. There was no visible reduction of the infection at 5dpi in ZF treated with low or intermediate drug concentrations, consistent with the survival curves and kinetic of 272 273 bacterial growth. A quantitative analysis revealed that high doses of clarithromycin reduced by 274 50% the number of embryos with abscesses (Figure 3E), and this drug effect was apparent in both the brain and the spinal cord (Figure 3F), albeit the impact of lower drug concentrations 275 was not significant. This indicates that clarithromycin exerts a beneficial effect by inhibiting 276 277 mycobacterial growth, preventing the development of abscesses within the CNS and protecting the embryos from bacterial killing. 278

279

## 280 Effects of imipenem on ZF survival and reduction of the pathological signs

To further confirm and extend the impact and usefulness of this biological system with respect to *in vivo* drug testing, embryos were exposed to water-soluble imipenem, a clinically relevant drug against *Mabs* known to act on L,D-transpeptidases (17, 27). A wide range of concentrations was tested, corresponding to 0.5X to 28X MIC of imipenem, and neither signs of toxicity-induced-killing nor developmental abnormalities were detected even at the highest 286 dose (data not shown). When assessing the effect of imipenem on infected ZF, no increased 287 survival was found with low drug concentrations. However, treatment with intermediate doses 288 led to a significant increase in survival and 100% of protection was observed in the presence of this highest drug concentration (Figure 4A). These survival rates correlated with the CFU loads 289 290 as intermediate and high doses of imipenem started to restrict bacterial growth at 3dpi (after two days of drug treatment) (Figure 4B). With the highest dose, there was a 3 Log<sub>10</sub> decline in 291 the CFU at 5dpi (four days of treatment) compared with the untreated control group. Time-292 lapse fluorescence microscopy further confirmed the in vivo efficacy of imipenem, illustrating 293 the inhibition of bacterial growth and disappearance of abscesses in the larval brain at 3 and 294 295 5dpi, respectively (Figure 4C). There was no visible reduction of the infection at 5dpi when 296 treated with low imipenem doses, consistent with the survival curves and kinetic of bacterial 297 growth. High doses significantly reduced the proportion of embryos with abscesses (Figure 4D), 298 a phenotypic effect that was particularly apparent in the brain on infected embryos (Figure 4E), indicating that imipenem reduces the pathology signs of the infection. 299

300 These results also prompted us to examine whether imipenem can counteract/alter the progression of an already established infection, especially when given at 3dpi when brain 301 abscesses are already apparent (Figure S1A). Death curves indicate that treatment with high 302 303 doses of imipenem effectively extended the life span of embryos with pre-existing abscesses 304 (Figure S1B). A large proportion (more than 60%) of the treated embryos survived to the infection compared to 10% for the non-treated individuals (P=0.008). The remaining 40% 305 306 embryos that died despite the treatment showed increased bacterial loads in the CNS (data not shown). The increased index of protection rate was associated to a significant decrease in the 307 number of embryos with abscesses (Figure S1C), particularly within the brain (Figure S1D). This 308

309 "curative" protocol shows that imipenem was able to cure embryos with pre-existing abscesses310 and to protect severely infected ZF.

311

#### 312 *In vivo* inhibition activity of imipenem on mycobacterial cording

Rough Mabs displays a dry texture with organized serpentine cords on agar plates (19, 28, 313 29) and large bacterial clumps consisting mainly of cords in liquid cultures (19). Our recent 314 studies also unraveled the presence of serpentine cords within the brain or spinal cord of 315 embryos infected with the rough morphotype and emphasized the role of cording in immune 316 evasion by preventing phagocytosis of *Mabs* by macrophages and neutrophils (19). Since cords 317 318 are easy to visualize and to numerate by fluorescence microscopy (Figure 5A), and because they promote extracellular replication, abscess formation and tissue damage, we investigated 319 320 whether exposure of infected embryos to imipenem may also affect the development of 321 mycobacterial cords. Figure 5B shows the presence of multiple cords within the brain at 5dpi (left panel) and the impact of imipenem treatment on the number of cords (right panel). 322

Quantitative analysis of the percentage of embryos with cords at 4dpi is shown in Figure 5C. The presence of low doses of imipenem has little impact on mycobacterial cords, although a reduction of the number of embryos with cords was detected at 4dpi. However, this effect was more pronounced with higher drug concentrations with only 20% of cord-laden embryos at 4dpi (compared to 60% for untreated embryos at 4dpi). This dose-dependent effect occurred essentially within the CNS whilst reduction of cord formation within the vasculature was not significant (Figure 5D).

#### 331 **DISCUSSION**

332 At a basic research level, the appropriate use of animal models can help to improve our 333 understanding of host-pathogen interactions. At a more applied level, preclinical evaluation of new drug compounds requires in vivo testing prior these can advance along the development 334 pipeline. However, in vivo animal studies, when possible, are usually costly and time-consuming 335 and present a major bottleneck in drug developments. Implementation of novel approaches, 336 expected to accelerate the *in vivo* efficacy assessment of drugs, is particularly justified in two 337 cases. First, such systems are useful for bacterial infections requiring extended periods of drug 338 treatment such as mice infected with M. tuberculosis, for which rapid in vivo assessment of 339 340 drug efficacy directly in infected mice using fluorescence imaging (30) or using improved firefly luciferase (31) were elegantly demonstrated. We similarly show in this study how the use of 341 342 fluorescence imaging can be useful in evaluating antimicrobial activity against Mabs. Second, 343 alternative biological systems are particularly relevant for infections lacking of a permissive animal model. In this context, we recently demonstrated the high susceptibility of ZF embryos 344 to Mabs and how the number of CNS abscesses may represent a marker for establishing in vivo 345 346 antibiotic activity against Mabs.

Due to its intrinsic and acquired resistance to commonly used antibiotics, treatment 347 348 becomes more complicated, thereby leading to high failure rates, stressing the need for new drug discovery. One of the key steps of drug discovery process is to identify and evaluate the *in* 349 vitro and in vivo potential of new hits against Mabs, which pre-requires adequate animal 350 351 models. Assessing the murine model which, following *i.v.* or aerosol infection, led only to 352 transient colonization. Therefore, the natural course of infection in immune-competent BALB/c mice impedes its use as a valuable animal model for drug susceptibility testing. Comparatively, 353 SCID mouse model has been shown to produce a chronic infection of *Mabs*, but this model has 354

355 not been used for drug testing (29, 32). However, granulocyte-macrophage colony-stimulating (GM-CSF) knockout mice have recently been used to develop a new animal model of persistent 356 357 pulmonary Mabs infection that can be used for preclinical efficacy testing of anti-microbial drugs (15). In particular, azithromycin treatment of *Mabs*-infected GM-CSF KO mice resulted in 358 a lower bacterial burden in the lungs and spleen, weight gain and significant improvement in 359 lung pathology (15). Another report proposed Nude mice as an adequate model for in vivo 360 361 chemotherapy studies (16). However, both models raised the question of the adaptive response in addition to the antibiotic activity in eradicating the bacilli. It was previously shown 362 that, albeit being a rapid-growing mycobacterium, Mabs infection was only controlled in mice 363 364 with a functional adaptive immune response (22), as compared to *M. chelonae*, which was cleared even in T cell-deficient mice. In addition, and despite the fact that both immune-365 366 compromised mice present a significant advance as compared to wild-type mice in preclinical 367 assessments, these models remain costly and time-consuming and remain most likely not suitable for a general use in drug screening campaigns. 368

New non-mammalian models of infection have been developed, including Drosophila 369 370 melanogaster (33, 34), Caenorhabditis elegans (35) or Danio rerio (36, 37) which offer several advantages in terms of speed, cost, technical convenience and ethical acceptability over the 371 372 mouse model. However, very few of these alternative models, except for the recent Drosophila model (34), have been reported for antibiotic assessments against Mabs. In this study, we 373 propose the ZF model, to visualize by non-invasive imaging the progressive infection of *Mabs* in 374 live animals, and to quantifying the effect of drug treatment. We successfully investigated the 375 suitability and sensitivity of two clinically relevant drugs, clarithromycin and imipenem, to 376 visualize in a dose- and time-dependent manner the dynamics of cord and abscess 377 formation/resorption. One major advantage of this model compared to mice is the ease and 378

rapidity of experimentation within a restricted time scale and low cost. That both drugs had a positive impact in terms of embryo survival was correlated to a significant reduction in the number of CFU and abscesses, demonstrating a proof of concept that ZF embryos are suitable for drug efficacy testing. Since *in vitro* studies demonstrated decreased MICs in the presence of imipenem for clarithromycin, minocycline, levofloxacin and moxifloxacin (38), future work should also address the *in vivo* efficacy of these drug combinations using the *Mabs*/ZF couple.

It is, however, noteworhty that despite of their unique features for the *in vivo* drug testing, 385 ZF embryos also present several disadvantages over mammalian models. In particular, there are 386 some important anatomical differences between ZF embryos and mammmals such as gills 387 388 instead of lungs, hematopoiesis occurring in the anterioir kidney instead of the bone marrow, lack on discernable lymph nodes as well as a very different reproductive system. In addition, 389 390 the natural lack of an adaptive immunity early in the development is very likely to affect the 391 outcome of the infection, thus making it difficult to directly correlating data obtained in ZF and in humans. In addition, as shown in this study, embryos allow to describing effects of antibiotics 392 during acute Mabs infections but not during the chronic stages of the disease, which can be 393 394 better modelled for instance using immuno-compromized mice (15). In a similar vein, since pharmacokinetics in are not known in ZF, it remains difficult at this stage to directly transpose 395 396 the MIC data obtained in ZF to humans. As a consequence, this biological system should 397 essentially be regarded as an early model for pre-clinical drug testing and/or to select for new active compounds which should then be evaluated in other models before clinical trials. 398 Nevertheless, the perspectives of application of these findings are multiple. First, this 399 400 method could be implemented to address the *in vivo* drug susceptibility profiles of clinical 401 isolates that include strains from CF and non-CF patients, as Mabs clinical strains are not uniformly susceptible to the currently used antibiotics. Due to these strain-to-strain variations 402

403 (17, 39), no optimal regimen has been established to cure *Mabs* infections and determining the susceptibility/resistance profile of clinical strains may greatly help the clinician to select optimal 404 405 drug treatments. It is worth mentioning that for this particular application, no absolute requirement for the tested strains to carry pTEC27 is needed, as visualization of fluorescent 406 407 bacteria is not necessary if assessing ZF survival only. Second, since the ZF is particularly amenable to mimic a CF-like micro-environment, by silencing the *cftr* expression level (40), this 408 system would also allow to comparing the therapeutic efficacy of clarithromycin and imipenem 409 (and perhaps other antibiotics) in a *cftr*-deficient environment as it remains to be established 410 whether a defect in CFTR affects susceptibility to drugs. Third, this method could be further 411 412 exploited to compare the intrinsic activity of antibiotics in vivo in embryos infected with the three species of the M. abscessus complex - M. abscessus sensu stricto, M. massiliense, and M. 413 414 *bolletii* - which are known to respond differently to antibiotics *in vitro* (41, 42).

Finally, the ZF embryo is particularly suited for high throughput screening as shown recently for *M. marinum* (36, 43, 44). Work is currently in progress in our laboratory to develop an *in vivo* platform for high-throughput screening of molecules against *Mabs* in order to speed up the process of identifying promising drug candidates, particularly warranted due to the extreme resistance of *Mabs* to most current antibiotics.

## 421 ACKNOWLEDGMENTS

We thank L. Ramakrishnan for the generous gift of pTEC27 and for helpful discussions and theMontpellier RIO Imaging and the SCME facilities at UM2.

This study was supported by the french National Research Agency (http://www.agence-424 nationale-recherche.fr/) (ZebraFlam ANR-10-MIDI-009and DIMYVIR ANR-13-BSV3-0007-01), the 425 426 European Community's Seventh Framework Programme (FP7-PEOPLE-2011-ITN) under grant agreement no. PITN-GA-2011-289209 for the Marie-Curie Initial Training Network 427 428 FishForPharma. We wish also to thank Vaincre La Mucoviscidose (http://www.vaincrelamuco.org/) for funding A Bernut (RF2011 06000446) and V Le Moigne 429 (RF20120600689) and the InfectioPôle Sud for funding part of the fish facility. 430

431

#### 433 **REFERENCES**

- Medjahed, H., J. L. Gaillard, and J. M. Reyrat. 2010. Mycobacterium abscessus: a new player in
   the mycobacterial field. Trends Microbiol 18:117-23.
- 436 2. Petrini, B. 2006. Mycobacterium abscessus: an emerging rapid-growing potential pathogen.
  437 Apmis 114:319-28.
- Roux, A. L., E. Catherinot, F. Ripoll, N. Soismier, E. Macheras, S. Ravilly, G. Bellis, M. A. Vibet, E.
   Le Roux, L. Lemonnier, C. Gutierrez, V. Vincent, B. Fauroux, M. Rottman, D. Guillemot, and J. L.
   Gaillard. 2009. Multicenter study of prevalence of nontuberculous mycobacteria in patients
   with cystic fibrosis in france. J Clin Microbiol 47:4124-8.
- Sanguinetti, M., F. Ardito, E. Fiscarelli, M. La Sorda, P. D'Argenio, G. Ricciotti, and G. Fadda.
   2001. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a
   patient with cystic fibrosis. J Clin Microbiol **39:**816-9.
- Gilljam, M., H. Schersten, M. Silverborn, B. Jonsson, and A. Ericsson Hollsing. 2010. Lung
  transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst
  Fibros 9:272-6.
- Aitken, M. L., A. Limaye, P. Pottinger, E. Whimbey, C. H. Goss, M. R. Tonelli, G. A. Cangelosi,
   M. A. Dirac, K. N. Olivier, B. A. Brown-Elliott, S. McNulty, and R. J. Wallace, Jr. 2012.
   Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant
   and cystic fibrosis center. Am J Respir Crit Care Med 185:231-2.
- 452 7. **Wallace, R. J., Jr., B. A. Brown, and D. E. Griffith.** 1998. Nosocomial outbreaks/pseudo-453 outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol **52:**453-90.
- Viana-Niero, C., K. V. Lima, M. L. Lopes, M. C. Rabello, L. R. Marsola, V. C. Brilhante, A. M.
   Durham, and S. C. Leao. 2008. Molecular characterization of Mycobacterium massiliense and
   Mycobacterium bolletii in isolates collected from outbreaks of infections after laparoscopic
   surgeries and cosmetic procedures. J Clin Microbiol 46:850-5.

- Zelazny, A. M., J. M. Root, Y. R. Shea, R. E. Colombo, I. C. Shamputa, F. Stock, S. Conlan, S.
   McNulty, B. A. Brown-Elliott, R. J. Wallace, Jr., K. N. Olivier, S. M. Holland, and E. P. Sampaio.
   2009. Cohort study of molecular identification and typing of Mycobacterium abscessus,
   Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol 47:1985-95.
- 462 10. Cullen, A. R., C. L. Cannon, E. J. Mark, and A. A. Colin. 2000. Mycobacterium abscessus infection
  463 in cystic fibrosis. Colonization or infection? Am J Respir Crit Care Med 161:641-5.
- 11. Tomashefski, J. F., Jr., R. C. Stern, C. A. Demko, and C. F. Doershuk. 1996. Nontuberculous
- 465 mycobacteria in cystic fibrosis. An autopsy study. Am J Respir Crit Care Med **154**:523-8.
- 466 12. Rodriguez, G., M. Ortegon, D. Camargo, and L. C. Orozco. 1997. latrogenic Mycobacterium
  467 abscessus infection: histopathology of 71 patients. Br J Dermatol 137:214-8.
- 46813.Griffith, D. E., T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland,
- R. Horsburgh, G. Huitt, M. F. lademarco, M. Iseman, K. Olivier, S. Ruoss, C. F. von Reyn, R. J.
  Wallace, Jr., and K. Winthrop. 2007. An official ATS/IDSA statement: diagnosis, treatment, and
  prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367-416.
- 472 14. Jeon, K., O. J. Kwon, N. Y. Lee, B. J. Kim, Y. H. Kook, S. H. Lee, Y. K. Park, C. K. Kim, and W. J.
- 473 Koh. 2009. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective
  474 analysis of 65 patients. Am J Respir Crit Care Med 180:896-902.
- 475 15. De Groote, M. A., L. Johnson, B. Podell, E. Brooks, R. Basaraba, and M. Gonzalez-Juarrero.
- 476 2013. GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against
  477 Mycobacterium abscessus. J Antimicrob Chemother In Press.
- 478 16. Lerat, I., E. Cambau, R. Roth Dit Bettoni, J. L. Gaillard, V. Jarlier, C. Truffot, and N. Veziris. 2013.
  479 In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis In Press.
- 480 17. Lavollay, M., V. Dubee, B. Heym, J. L. Herrmann, J. L. Gaillard, L. Gutmann, M. Arthur, and J. L.

481 Mainardi. 2013. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus
 482 complex. Clin Microbiol Infect In Press.

- 483 18. Cortes, M., A. K. Singh, J. M. Reyrat, J. L. Gaillard, X. Nassif, and J. L. Herrmann. 2011.
  484 Conditional gene expression in Mycobacterium abscessus. PLoS One 6:e29306.
- Bernut, A., J. L. Herrmann, K. Kissa, J. F. Dubremetz, J. L. Gaillard, G. Lutfalla, and L. Kremer.
  The zebrafish model reveals specific pathophysiological traits and neurotropism of
  Mycobacterium abscessus. Under revision.
- Talati, N. J., N. Rouphael, K. Kuppalli, and C. Franco-Paredes. 2008. Spectrum of CNS disease
  caused by rapidly growing mycobacteria. Lancet Infect Dis 8:390-8.
- 490 21. Lee, M. R., A. Cheng, Y. C. Lee, C. Y. Yang, C. C. Lai, Y. T. Huang, C. C. Ho, H. C. Wang, C. J. Yu,
- and P. R. Hsueh. 2011. CNS infections caused by Mycobacterium abscessus complex: clinical
   features and antimicrobial susceptibilities of isolates. J Antimicrob Chemother 67:222-5.
- 493 22. Rottman, M., E. Catherinot, P. Hochedez, J. F. Emile, J. L. Casanova, J. L. Gaillard, and C.
- 494 Soudais. 2007. Importance of T cells, gamma interferon, and tumor necrosis factor in immune
  495 control of the rapid grower Mycobacterium abscessus in C57BL/6 mice. Infect Immun 75:5898496 907.
- 497 23. Catherinot, E., J. Clarissou, G. Etienne, F. Ripoll, J. F. Emile, M. Daffe, C. Perronne, C. Soudais, J.
- 498 L. Gaillard, and M. Rottman. 2007. Hypervirulence of a rough variant of the Mycobacterium
  499 abscessus type strain. Infect Immun 75:1055-8.
- 500 24. Woods, G. L., B. A. Brown-Elliott, P. S. Conville, E. P. Desmond, G. S. Hall, G. Lin, G. E. Pfyffer, J.

501 C. Ridderhof, S. H. Siddiqi, R. J. Wallace, N. G. Warren, and F. G. Witebsky. 2011. Susceptibility
 502 testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard,
 503 Second Edition. M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.

- 504 25. Lamason, R. L., M. A. Mohideen, J. R. Mest, A. C. Wong, H. L. Norton, M. C. Aros, M. J. Jurynec,
- 505 X. Mao, V. R. Humphreville, J. E. Humbert, S. Sinha, J. L. Moore, P. Jagadeeswaran, W. Zhao, G.
- 506 Ning, I. Makalowska, P. M. McKeigue, D. O'Donnell, R. Kittles, E. J. Parra, N. J. Mangini, D. J.
- 507 Grunwald, M. D. Shriver, V. A. Canfield, and K. C. Cheng. 2005. SLC24A5, a putative cation
- 508 exchanger, affects pigmentation in zebrafish and humans. Science **310**:1782-6.

509 26. Adams, K. N., K. Takaki, L. E. Connolly, H. Wiedenhoft, K. Winglee, O. Humbert, P. H. Edelstein,

- 510 C. L. Cosma, and L. Ramakrishnan. 2011. Drug tolerance in replicating mycobacteria mediated
  511 by a macrophage-induced efflux mechanism. Cell 145:39-53.
- 512 27. Lavollay, M., M. Fourgeaud, J. L. Herrmann, L. Dubost, A. Marie, L. Gutmann, M. Arthur, and J.
- L. Mainardi. 2011. The peptidoglycan of Mycobacterium abscessus is predominantly crosslinked by L,D-transpeptidases. J Bacteriol 193:778-82.
- 515 28. **Medjahed, H., and J. M. Reyrat.** 2009. Construction of Mycobacterium abscessus defined 516 glycopeptidolipid mutants: comparison of genetic tools. Appl Environ Microbiol **75:**1331-8.

517 29. Howard, S. T., E. Rhoades, J. Recht, X. Pang, A. Alsup, R. Kolter, C. R. Lyons, and T. F. Byrd.

- 518 2006. Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough 519 morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an 520 invasive phenotype. Microbiology **152:**1581-90.
- 521 30. Zelmer, A., P. Carroll, N. Andreu, K. Hagens, J. Mahlo, N. Redinger, B. D. Robertson, S. Wiles, T.
- 522 H. Ward, T. Parish, J. Ripoll, G. J. Bancroft, and U. E. Schaible. 2012. A new in vivo model to test

523 anti-tuberculosis drugs using fluorescence imaging. J Antimicrob Chemother **67**:1948-60.

- 524 31. Andreu, N., A. Zelmer, S. L. Sampson, M. Ikeh, G. J. Bancroft, U. E. Schaible, S. Wiles, and B. D.
- 525 Robertson. 2013. Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis
  526 using an improved firefly luciferase. J Antimicrob Chemother.
- 527 32. Byrd, T. F., and C. R. Lyons. 1999. Preliminary characterization of a Mycobacterium abscessus
  528 mutant in human and murine models of infection. Infect Immun 67:4700-7.
- 529 33. Oh, C. T., C. Moon, M. S. Jeong, S. H. Kwon, and J. Jang. 2013. Drosophila melanogaster model
   530 for Mycobacterium abscessus infection. Microbes Infect.
- 34. Oh, C. T., C. Moon, O. K. Park, S. H. Kwon, and J. Jang. 2014. Novel drug combination for
  Mycobacterium abscessus disease therapy identified in a Drosophila infection model. J
  Antimicrob Chemother.

- 534 35. Squiban, B., and C. L. Kurz. 2011. C. elegans: an all in one model for antimicrobial drug
  535 discovery. Curr Drug Targets 12:967-77.
- 536 36. Takaki, K., C. L. Cosma, M. A. Troll, and L. Ramakrishnan. 2012. An in vivo platform for rapid
  537 high-throughput antitubercular drug discovery. Cell Rep 2:175-84.
- Takaki, K., J. M. Davis, K. Winglee, and L. Ramakrishnan. 2013. Evaluation of the pathogenesis
   and treatment of Mycobacterium marinum infection in zebrafish. Nat Protoc 8:1114-24.
- Miyasaka, T., H. Kunishima, M. Komatsu, K. Tamai, K. Mitsutake, K. Kanemitsu, Y. Ohisa, H.
  Yanagisawa, and M. Kaku. 2007. In vitro efficacy of imipenem in combination with six
  antimicrobial agents against Mycobacterium abscessus. Int J Antimicrob Agents 30:255-8.
- Shen, G. H., B. D. Wu, S. T. Hu, C. F. Lin, K. M. Wu, and J. H. Chen. 2010. High efficacy of
  clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J
  Antimicrob Agents 35:400-4.
- 546 40. Phennicie, R. T., M. J. Sullivan, J. T. Singer, J. A. Yoder, and C. H. Kim. 2010. Specific resistance
  547 to Pseudomonas aeruginosa infection in zebrafish is mediated by the cystic fibrosis
  548 transmembrane conductance regulator. Infect Immun 78:4542-50.
- Bastian, S., N. Veziris, A. L. Roux, F. Brossier, J. L. Gaillard, V. Jarlier, and E. Cambau. 2011.
  Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus
  group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 55:775-81.
- Kim, H. Y., B. J. Kim, Y. Kook, Y. J. Yun, J. H. Shin, B. J. Kim, and Y. H. Kook. 2010.
  Mycobacterium massiliense is differentiated from Mycobacterium abscessus and
  Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and
  clarithromycin susceptibility patterns. Microbiol Immunol 54:347-53.
- Carvalho, R., J. de Sonneville, O. W. Stockhammer, N. D. Savage, W. J. Veneman, T. H.
  Ottenhoff, R. P. Dirks, A. H. Meijer, and H. P. Spaink. 2011. A high-throughput screen for
  tuberculosis progression. PLoS One 6:e16779.

559	44.	Spaink, H. P., C. Cui, M. I. Wiweger, H. J. Jansen, W. J. Veneman, R. Marin-Juez, J. de					
560		Sonneville, A. Ordas, V. Torraca, W. van der Ent, W. P. Leenders, A. H. Meijer, B. E. Snaar-					
561		Jagalska, and R. P. Dirks. 2013. Robotic injection of zebrafish embryos for high-throughput					
562		screening in disease models. Methods <b>62:</b> 246-54.					
563							

565 **FIGURE LEGENDS** 

566

Figure 1. Kinetics of colonization of *M. abscessus* in aerosolised or intravenously infected BALB/c mice. (A) Mice were aerosolized by  $4 \times 10^7$  CFU/ml of *Mabs*. Animal were then sacrificed at days 1, 3, 8, 27 prior to CFU counting in the liver, spleen and lungs. Results are expressed as the log units of CFU. (B) Mice were challenged *i.v.*  $10^6$  CFU of *Mabs*. Animals were then sacrificed at days 1, 15 and 30 to determine the CFU counts in the different organs. Results are representative of 2-3 independent experiments and Log CFU are expressed as the mean ± standard error (n=5-7 mice for each time point).

574

Figure 2. Experimental protocol to assess the *in vivo* drug activity on *M. abscessus* infection. ZF embryos were *i.v.* infected with  $\approx$ 300 CFU of *Mabs* expressing dtTomato and distributed and incubated into 96-wells plate (1). From 1dpi, embryos were exposed to the drugs of interest which were directly added to the wells. Drugs are then removed and daily renewed for 5 days (2). To determinate the *in vivo* antibacterial effects of the drugs, the embryo survival, the bacterial loads and the evolution of the infection process were monitored at a spatiotemporal level by videomicroscopy (3).

582

**Figure 3.** *In vivo* characterization of clarithromycin activity on *M. abscessus* infection. (A-F) Embryos were soaked in clarithromycin at 1.7X, MIC 17X or 170X the MIC for 5 days. The red bar indicates the start and duration of treatment. (A) Survival of uninfected embryos treated with various doses of clarithromycin and compared to mock controls (DMSO 1%) (n=20 for each, representative of three independent experiments). Representative microscopy image of an untreated (inset, upper panel) or drug treated-embryo (inset, lower panel) at 8dpf. Clarithromycin appears toxic at the highest concentration as evidenced by the presence

590 development abnormalities and the increased mortality rate in the drug-exposed embryos compared to the mock control (p=0.028, log-rank test). (B) Survival of infected Mabs treated at 591 various doses of clarithromycin and compared to untreated infected embryos (≈300 CFU, n=20, 592 representative of three independent experiments). A significant increased survival was 593 observed in the infected-embryos exposed to the highest drug concentration (p=0.029, log-rank 594 test). (C) Bacterial loads of untreated or treated-embryos (≈400 CFU). Results are expressed as 595 596 mean Log<sub>10</sub> CFU per embryo from three independent experiments. A significant reduction in bacterial burdens with 170X the MIC in drug treated-embryos is observed at 5dpi. (D) 597 Spatiotemporal visualization of the infection by *Mabs* expressing dtTomato (≈300 CFU) in 598 untreated or drug treated-embryos. The representative fluorescence and transmission overlay 599 of whole embryos are shown. The yolk is auto-fluorescent. (E) Frequency of abscesses in whole 600 601 untreated or drug treated-embryos over 13dpi (≈300 CFU; average of three independent 602 experiments). Infected embryos developed significantly less abscesses in the presence clarithromycin at 170X the MIC than untreated infected-embryos. (F) Average localization of 603 abscesses of the infected embryos in (E). Mabs-infected ZF developed significantly less 604 605 abscesses within the brain and the spinal when exposed to the highest clarithromycin dose as compared to untreated infected-ZF. For (c) statistics were calculated using one-way ANOVA or 606 607 for (e) and (f) with Fisher's exact test comparing each category of drug-treated embryos to 608 untreated control. Error bars represent the standard errors. \*\*p<0.01.

609

Figure 4. Imipenem treatment cures *M. abscessus*-infected embryos. (A-E) From 1dpi,
embryos were exposed for 5 days to imipenem concentrations corresponding to 0.5X, 5X or 28X
the MIC. (A) Survival of infected *Mabs* R treated at various doses of imipenem and compared to
untreated infected embryos (≈300 CFU, n=20, representative of three independent

614 experiments). Survival of treated R-infected embryos is dose-dependent. Significant increased survival was observed in infected-embryos exposed to 5 X and 28X MIC of imipenem. The red 615 616 bar indicates the start and duration of treatment. (B) Bacterial loads of untreated or imigenem treated-embryos (≈400 CFU). Results are expressed as mean Log<sub>10</sub> CFU per embryo from three 617 independent experiments. A significant decreased of bacterial loads is already observed after 618 619 3dpi in the 28X MIC imipenem treated-embryos. (C) Spatiotemporal visualization of the 620 infection by *Mabs* expressing dtTomato (≈300 CFU) in untreated or imipenem treated-embryos. The representative fluorescence and transmission overlay of whole embryos are shown. (D) 621 Frequency of abscesses in whole untreated or imipenem-treated embryos over 13dpi (~300 622 623 CFU, average of three independent experiments). Only the 28X MIC imipenem treated-embryos developed significantly fewer abscesses than untreated infected-embryos. (E) Average 624 625 localization of abscesses of the infected embryos in (D). 5X and 28X MIC of imipenem treated-626 embryos infected by Mabs developed fewer abscesses within the brain than untreated infected-embryos. For (B) statistics were calculated using one-way ANOVA or for (D) and (E) 627 with Fisher's exact test comparing each category of imipenem-treated embryos to untreated 628 629 control. Error bars represent the standard error. \*p=0.02, \*\*p<0.01, \*\*\*p<0.001.

630

Figure 5. Imipenem treatment decreases the early pathophysiological signs within the CNS. (A-D). dtTomato-expressing *Mabs* ( $\approx$ 300 CFU) are injected in 30hpf embryos (n=15, average of three independent experiments). From 1dpi, embryos were exposed to imipenem at 0.5X, 5X or 28X MIC during 5 days. (A) Fluorescence microscopy of a typical R serpentine cord. Scale bar, 100µm. (B) Fluorescence and DIC overlay of whole heads of a 28X MIC imipenem-treated and untreated infected embryos with red fluorescent *M. abs* showing serpentine cord (white arrow). Scale bars, 100µm. (C) Percentage of embryos with cords in whole untreated and

638 imipenem-treated embryos at 4dpi. A significant reduction in the proportion of embryos with cords was observed when embryos were treated with the highest (28X MIC) imipenem 639 concentration. (D) Average localization of cord of the infected embryos in (C). Infected embryos 640 treated with the intermediate (5X MIC) and high (28X MIC) imipenem doses developed 641 significantly fewer serpentine cords within the CNS compared to untreated infected-embryos. 642 643 For (C) and (D), statistics were calculated using Fisher's exact test comparing each category of 644 imipenem-treated embryos to untreated control. All results are expressed as the average from 645 three independent experiments and error bars represent the standard errors.





Figure 1. Kinetics of colonization of *M. abscessus* in aerosolised or intravenously infected BALB/c mice. (A) Mice were aerosolized by  $4 \times 10^7$  CFU/ml of *Mabs*. Animal were then sacrificed at days 1, 3, 8, 27 prior to CFU counting in the liver, spleen and lungs. Results are expressed as the log units of CFU. (B) Mice were challenged *i.v.* 10<sup>6</sup> CFU of *Mabs*. Animals were then sacrificed at days 1, 15 and 30 to determine the CFU counts in the different organs. Results are representative of 2-3 independent experiments and Log CFU are expressed as the mean ± standard error (n=5-7 mice for each time point).



**Figure 2.** Experimental protocol to assess the *in vivo* drug activity on *M. abscessus* infection. ZF embryos were *i.v.* infected with  $\approx$ 300 CFU of *Mabs* expressing dtTomato and distributed and incubated into 96-wells plate (1). From 1dpi, embryos were exposed to the drugs of interest which were directly added to the wells. Drugs are then removed and daily renewed for 5 days (2). To determinate the *in vivo* antibacterial effects of the drugs, the embryo survival, the bacterial loads and the evolution of the infection process were monitored at a spatiotemporal level by videomicroscopy (3).




Figure 3. In vivo characterization of clarithromycin activity on M. abscessus infection. (A-F) Embryos were soaked in clarithromycin at 1.7X, MIC 17X or 170X the MIC for 5 days. The red bar indicates the start and duration of treatment. (A) Survival of uninfected embryos treated with various doses of clarithromycin and compared to mock controls (DMSO 1%) (n=20 for each, representative of three independent experiments). Representative microscopy image of an untreated (inset, upper panel) or drug treated-embryo (inset, lower panel) at 8dpf. Clarithromycin appears toxic at the highest concentration as evidenced by the presence development abnormalities and the increased mortality rate in the drugexposed embryos compared to the mock control (p=0.028, log-rank test). (B) Survival of infected Mabs treated at various doses of clarithromycin and compared to untreated infected embryos (≈300 CFU, n=20, representative of three independent experiments). A significant increased survival was observed in the infected-embryos exposed to the highest drug concentration (p=0.029, log-rank test). (C) Bacterial loads of untreated or treated-embryos ( $\approx$ 400 CFU). Results are expressed as mean Log<sub>10</sub> CFU per embryo from three independent experiments. A significant reduction in bacterial burdens with 170X the MIC in drug treated-embryos is observed at 5dpi. (D) Spatiotemporal visualization of the infection by Mabs expressing dtTomato (≈300 CFU) in untreated or drug treated-embryos. The representative fluorescence and transmission overlay of whole embryos are shown. The yolk is auto-fluorescent. (E) Frequency of abscesses in whole untreated or drug treated-embryos over 13dpi (≈300 CFU; average of three independent experiments). Infected embryos developed significantly less abscesses in the presence clarithromycin at 170X the MIC than untreated infected-embryos. (F) Average localization of abscesses of the infected embryos in (E). Mabs-infected ZF developed significantly less abscesses within the brain and the spinal when exposed to the highest clarithromycin dose as compared to untreated infected-ZF. For (c) statistics were calculated using one-way ANOVA or for (e) and (f) with Fisher's exact test comparing each category of drug-treated embryos to untreated control. Error bars represent the standard errors. \*\*p<0.01.





Figure 4. Imipenem treatment cures M. abscessus-infected embryos. (A-E) From 1dpi, embryos were exposed for 5 days to imipenem concentrations corresponding to 0.5X, 5X or 28X the MIC. (A) Survival of infected Mabs R treated at various doses of imipenem and compared to untreated infected embryos (≈300 CFU, n=20, representative of three independent experiments). Survival of treated R-infected embryos is dose-dependent. Significant increased survival was observed in infected-embryos exposed to 5 X and 28X MIC of imipenem. The red bar indicates the start and duration of treatment. (B) Bacterial loads of untreated or imipenem treatedembryos ( $\approx$ 400 CFU). Results are expressed as mean Log<sub>10</sub> CFU per embryo from three independent experiments. A significant decreased of bacterial loads is already observed after 3dpi in the 28X MIC imipenem treatedembryos. (C) Spatiotemporal visualization of the infection by Mabs expressing dtTomato (≈300 CFU) in untreated or imipenem treated-embryos. The representative fluorescence and transmission overlay of whole embryos are shown. (D) Frequency of abscesses in whole untreated or imipenem-treated embryos over 13dpi (≈300 CFU, average of three independent experiments). Only the 28X MIC imipenem treated-embryos developed significantly fewer abscesses than untreated infected-embryos. (E) Average localization of abscesses of the infected embryos in (D). 5X and 28X MIC of imipenem treated-embryos infected by Mabs developed fewer abscesses within the brain than untreated infected-embryos. For (B) statistics were calculated using one-way ANOVA or for (D) and (E) with Fisher's exact test comparing each category of imipenem-treated embryos to untreated control. Error bars represent the standard error. \*p=0.02, \*\*p<0.01, \*\*\*p<0.001.



**Figure 5. Imipenem treatment decreases the early pathophysiological signs within the CNS. (A-D)**. dtTomatoexpressing *Mabs* (≈300 CFU) are injected in 30hpf embryos (n=15, average of three independent experiments). From 1dpi, embryos were exposed to imipenem at 0.5X, 5X or 28X MIC during 5 days. **(A)** Fluorescence microscopy of a typical R serpentine cord. Scale bar, 100µm. **(B)** Fluorescence and DIC overlay of whole heads of a 28X MIC imipenem-treated and untreated infected embryos with red fluorescent *M. abs* showing serpentine cord (white arrow). Scale bars, 100µm. **(C)** Percentage of embryos with cords in whole untreated and imipenemtreated embryos at 4dpi. A significant reduction in the proportion of embryos with cords was observed when embryos were treated with the highest (28X MIC) imipenem concentration. **(D)** Average localization of cord of the infected embryos in (C). Infected embryos treated with the intermediate (5X MIC) and high (28X MIC) imipenem doses developed significantly fewer serpentine cords within the CNS compared to untreated infectedembryos. For (C) and (D), statistics were calculated using Fisher's exact test comparing each category of imipenem-treated embryos to untreated control. All results are expressed as the average from three independent experiments and error bars represent the standard errors. SUPPLEMENTAL MATERIAL

## *In vivo* assessment of drug efficacy against *Mycobacterium abscessus* using the embryonic zebrafish test system

Audrey Bernut<sup>1</sup>, Vincent Le Moigne<sup>3</sup>, Tiffany Lesne<sup>1</sup>, Georges Lutfalla<sup>1</sup>, Jean-Louis Herrmann<sup>3</sup> and Laurent Kremer<sup>1,2,#</sup>




Figure S1. Exposure to imipenem overcomes and protects against severe *M. abscessus* infections. (A-C) dtTomato expressing *Mabs* ( $\approx$ 300 CFU) were injected in 30hpf embryos. From 3dpi, embryos were exposed during 5 days to imipenem at 0.5X, 5X or 28X MIC. (A) Schematic representation illustrating the "curing" protocol used as well as the infection status of the embryos at 3dpi (numerous abscesses within the CNS) when the drug treatment is applied. (B) Survival of infected *Mabs* treated at various doses of imipenem and compared to untreated infected embryos (n=20-30), representative of three independent experiments). A significant increased survival was observed in embryos exposed to the highest (28X MIC) imipenem dose. The red bar indicates the start and duration of treatment. (C) Frequency of *Mabs* abscesses in whole untreated or imipenemtreated embryos over 13dpi. Data are expressed as the average of three independent experiments. MIC 5X and MIC 28X imipenem treated-embryos infected by *Mabs* developed significantly fewer abscesses than untreated infected embryos infected by *Mabs* developed significantly fewer abscesses of (C). 28X MIC imipenem treated-embryos. For (C) and (D) statistics were calculated using Fisher's exact test comparing each category of imipenem-treated embryos to untreated control. All results are expressed as the average from two or three independent experiments and error bars represent the standard errors. \*\*p<0.01, \*\*\*p<0.001.

**Table S1.** Minimal inhibitory concentrations of several drugs against *M. abscessus* using the midrodilution method in cation-adjusted Mueller-Hinton (MH) broth or on LB agar. Antibiotics used in infected ZF are shown in bold. Results are expressed in  $\mu$ M and  $\mu$ g/ml.

Antibiotic	Molecular weight	Solvent	MIC MH broth		MIC LB agar	
			μM	µg/mL	μM	μg/mL
Clarithromycin	748	DMSO	4	3.0	0.7	0.5
Cefoxitin	427	DMSO	60	25.6	35	15
Amikacin	586	H <sub>2</sub> O	125	73.25	26	15
Isoniazid	137	H <sub>2</sub> O	1000	137	365	50
Erythromycin	734	DMSO	125	91.75	10	7.5
Imipenem	299	H <sub>2</sub> O	60	17.94	3.3	1
Thiacetazone	236	DMSO	1000	236	42	10